Compounds > s 16020-2
Page last updated: 2024-09-05

s 16020-2 and Experimental Neoplasms

s 16020-2 has been researched along with Experimental Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berlion, M; Bourhis, J; Eschwege, F; Frascogna, V; Lucas, C; Maggiorella, L; Poullain, MG; Razy, SD1
Atassi, G; Bisagni, E; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D; Visalli, M1
Anstett, M; Atassi, G; Bisagni, E; Casabianca-Pignede, MR; Léonce, S; Perez, V; Pierré, A1
Atassi, G; Chaminade, F; Decaestecker, C; Farinelle, S; Fontaine, J; Gordower, L; Kiss, R; Malonne, H; Saucier, JM1

Other Studies

4 other study(ies) available for s 16020-2 and Experimental Neoplasms

ArticleYear
The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:7

    Topics: Animals; Antineoplastic Agents, Phytogenic; Carbazoles; Cell Division; Combined Modality Therapy; Ellipticines; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mouth Mucosa; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyridines; Radiotherapy; Stomatitis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Breast Neoplasms; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Ellipticines; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia P388; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured

1996
In vitro cytotoxicity of S16020-2, a new olivacine derivative.
    Investigational new drugs, 1996, Volume: 14, Issue:2

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Ellipticines; Ethidium; Humans; Isoenzymes; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Neoplastic Stem Cells; Phenotype; Tumor Cells, Cultured

1996
In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:9

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Doxorubicin; Drug Screening Assays, Antitumor; Ellipticines; Etoposide; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Experimental; Topoisomerase II Inhibitors; Tumor Cells, Cultured

2000